Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis

Luca Richeldi

Unità Operativa Complessa di Pneumologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome

Arata Azuma

Clinical Research Center, Mihara General Hospital, Saitama, Japan

Vincent Cottin

Université Claude Bernard Lyon 1, Lyon, France

Michael Kreuter

Center for Pulmonary Medicine, Department of Pneumology, Mainz University Medical Center, Mainz, Germany

Toby M. Maher

Fernando J. Martinez

Justin M. Oldham

Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor

Claudia Valenzuela

Department of Pulmonology, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Madrid

Emmanuelle Clerisme-Beaty

Therapy Area Inflammation Medicine, Boehringer Ingelheim International, Ingelheim am Rhein, Germany

Maud Gordat

Clinical Development and Operation Department, Boehringer Ingelheim, Reims, France

Daniel Wachtlin

Department of Biostatistics and Data Sciences, Boehringer Ingelheim Pharma, Ingelheim am Rhein, Germany

Yi Liu

Christina Schlecker

Global Patient Safety and Pharmacovigilance, Boehringer Ingelheim International, Ingelheim am Rhein, Germany

Susanne Stowasser

Therapy Area Inflammation Medicine, Boehringer Ingelheim International, Ingelheim am Rhein, Germany

Donald F. Zoz

Global Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT

Marlies S. Wijsenbeek